Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study

Orphanet Journal of Rare Diseases

Ans T van der Ploeg⁹  Pieter A van Doorn³  Arnold JJ Reuser⁴  Michelle E Kruijshaar⁹  Jan JGM Verschuuren¹  Catharina G Faber²  Nicolette C Notermans⁸  Anneke J van der Kooi^1,10  Jan BM Kuks⁶  Baziel GM van Engelen⁷  Marianne de Visser^1,10  John H Wokke⁸  Francois PJ Karstens⁵  Wim CJ Hop^1,11  Nadine AME van der Beek⁹  Juna M de Vries⁹ 

[1] Department of Neurology, Leiden University Medical Center, Leiden, the Netherlands;Department of Neurology, Maastricht University Medical Center, Maastricht, the Netherlands;Department of Neurology & Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands;Department of Clinical Genetics & Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands;Department of Internal Medicine & Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands;Department of Neurology, University Medical Center Groningen, Groningen, the Netherlands;Department of Neurology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands;Department of Neurology, Rudolf Magnus Institute of Neurosciences, University Medical Center Utrecht, Utrecht, the Netherlands;Department of Pediatrics & Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands;Department of Neurology, Academic Medical Center, Amsterdam, the Netherlands;Department of Epidemiology and Biostatistics, Erasmus MC University Medical Center, Rotterdam, the Netherlands

关键词: Lung function;    Muscle strength;    Lysosomal storage disorder;    Enzyme replacement therapy;    Alglucosidase alfa;    Acid α-glucosidase;    OMIM number 232300;    Glycogen storage disease type II;    Pompe disease;   

Others  :  864197
DOI  :  10.1186/1750-1172-7-73

 received in 2012-06-18, accepted in 2012-09-19,  发布年份 2012

【 摘 要 】

Background

Enzyme replacement therapy (ERT) in adults with Pompe disease, a progressive neuromuscular disorder, is of promising but variable efficacy. We investigated whether it alters the course of disease, and also identified potential prognostic factors.

Methods

Patients in this open-label single-center study were treated biweekly with 20 mg/kg alglucosidase alfa. Muscle strength, muscle function, and pulmonary function were assessed every 3–6 months and analyzed using repeated-measures ANOVA.

Results

Sixty-nine patients (median age 52.1 years) were followed for a median of 23 months. Muscle strength increased after start of ERT (manual muscle testing 1.4 percentage points per year (pp/y); hand-held dynamometry 4.0 pp/y; both p < 0.001). Forced vital capacity (FVC) remained stable when measured in upright, but declined in supine position (−1.1 pp/y; p = 0.03). Muscle function did not improve in all patients (quick motor function test 0.7 pp/y; p = 0.14), but increased significantly in wheelchair-independent patients and those with mild and moderate muscle weakness.

Relative to the pre-treatment period (49 patients with 14 months pre-ERT and 22 months ERT median follow-up), ERT affected muscle strength positively (manual muscle testing +3.3 pp/y, p < 0.001 and hand-held dynamometry +7.9 pp/y, p < 0.001). Its effect on upright FVC was +1.8 pp/y (p = 0.08) and on supine FVC +0.8 (p = 0.38). Favorable prognostic factors were female gender for muscle strength, and younger age and better clinical status for supine FVC.

Conclusions

We conclude that ERT positively alters the natural course of Pompe disease in adult patients; muscle strength increased and upright FVC stabilized. Functional outcome is probably best when ERT intervention is timely.

【 授权许可】

   
2012 de Vries et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Engel AG HR: Acid maltase deficiency. In Myology: basic and clinical. Edited by Engel AF-AC. McGraw-Hill, New York; 1994:1533-1553.
• [2]Fukuda T, Ewan L, Bauer M, Mattaliano RJ, Zaal K, Ralston E, Plotz PH, Raben N: Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Ann Neurol 2006, 59:700-708.
• [3]Hirschhorn R, Reuser AJJ: Glycogen storage disease type II; acid alpha-glucosidase (acid maltase) deficiency. In The Metabolic and Molecular Bases of Inherited Disease. 8th edition. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. McGraw-Hill, New York; 2001:3389-3420.
• [4]Thurberg BL, Lynch Maloney C, Vaccaro C, Afonso K, Tsai AC, Bossen E, Kishnani PS, O'Callaghan M: Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 2006, 86:1208-1220.
• [5]Hagemans ML, Winkel LP, Van Doorn PA, Hop WJ, Loonen MC, Reuser AJ, Van der Ploeg AT: Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain 2005, 128:671-677.
• [6]Kishnani PS, Hwu WL, Mandel H, Nicolino M, Yong F, Corzo D, Infantile-Onset Pompe Disease Natural History Study Group: A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006, 148:671-676.
• [7]Laforet P, Nicolino M, Eymard PB, Puech JP, Caillaud C, Poenaru L, Fardeau M: Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation. Neurology 2000, 55:1122-1128.
• [8]Muller-Felber W, Horvath R, Gempel K, Podskarbi T, Shin Y, Pongratz D, Walter MC, Baethmann M, Schlotter-Weigel B, Lochmüller H, Schoser B: Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients. Neuromuscul Disord 2007, 17:698-706.
• [9]van den Hout HM, Hop W, van Diggelen OP, Smeitink JA, Smit GP, Poll-The BT, Bakker HD, Loonen MC, de Klerk JB, Reuser AJ, van der Ploeg AT: The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003, 112:332-340.
• [10]Van der Beek NA, Hagemans ML, Reuser AJ, Hop WC, Van der Ploeg AT, Van Doorn PA, Wokke JH: Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 2009, 19:113-117.
• [11]Wokke JH, Escolar DM, Pestronk A, Jaffe KM, Carter GT, van den Berg LH, Florence JM, Mayhew J, Skrinar A, Corzo D, Laforet P: Clinical features of late-onset Pompe disease: a prospective cohort study. Muscle Nerve 2008, 38:1236-1245.
• [12]van der Ploeg AT, Reuser AJ: Pompe's disease. Lancet 2008, 372:1342-1353.
• [13]van der Beek NA, van Capelle CI, van der Velden-van Etten KI, Hop WC, van den Berg B, Reuser AJ, van Doorn PA, van der Ploeg AT, Stam H: Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease. Mol Genet Metab 2011, 104:129-136.
• [14]Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT: Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 2005, 64:2139-2141.
• [15]Winkel LP, Hagemans ML, van Doorn PA, Loonen MC, Hop WJ, Reuser AJ, van der Ploeg AT: The natural course of non-classic Pompe's disease; a review of 225 published cases. J Neurol 2005, 252:875-884.
• [16]Amalfitano A, Bengur AR, Morse RP, Majure JM, Case LE, Veerling DL, Mackey J, Kishnani P, Smith W, McVie-Wylie A, Sullivan JA, Hoganson GE, Phillips JA 3rd, Schaefer GB, Charrow J, Ware RE, Bossen EH, Chen YT: Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001, 3:132-138.
• [17]Kishnani PS, Corzo D, Nicolino M, Mandel H, Hwu WL, Leslie N, Levine J, Spencer C, McDonald M, Li J, Dumontier J, Halberthal M, Chien YH, Hopkin R, Vijayaraghavan S, Gruskin D, Bartholomew D, van der Ploeg A, Clancy JP, Parini R, Morin G, Beck M, De la Gastine GS, Jokic M, Thurberg B, Richards S, Bali D, Davison M, Worden MA, Chen YT, Wraith JE: Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 2007, 68:99-109.
• [18]Kishnani PS, Nicolino M, Voit T, Rogers RC, Tsai AC, Waterson J, Herman GE, Amalfitano A, Thurberg BL, Richards S, Davison M, Corzo D, Chen YT: Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr 2006, 149:89-97.
• [19]Klinge L, Straub V, Neudorf U, Schaper J, Bosbach T, Görlinger K, Wallot M, Richards S, Voit T: Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II clinical trial. Neuromuscul Disord 2005, 15:24-31.
• [20]Klinge L, Straub V, Neudorf U, Voit T: Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Neuropediatrics 2005, 36:6-11.
• [21]Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT: Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 2000, 356:397-398.
• [22]Van den Hout JM, Kamphoven JH, Winkel LP, Arts WF, De Klerk JB, Loonen MC, Vulto AG, Cromme-Dijkhuis A, Weisglas-Kuperus N, Hop W, Van Hirtum H, Van Diggelen OP, Boer M, Kroos MA, Van Doorn PA, Van der Voort E, Sibbles B, Van Corven EJ, Brakenhoff JP, Van Hove J, Smeitink JA, de Jong G, Reuser AJ, Van der Ploeg AT: Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk. Pediatrics 2004, 113:e448-e457.
• [23]Van den Hout JM, Reuser AJ, de Klerk JB, Arts WF, Smeitink JA, Van der Ploeg AT: Enzyme therapy for pompe disease with recombinant human alpha-glucosidase from rabbit milk. J Inherit Metab Dis 2001, 24:266-274.
• [24]Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R, Rigoldi M, Moglia A, Costa A, Carlucci A, Danesino C, Pittis MG, Dardis A, Ravaglia S: Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 2010, 33:727-735.
• [25]Orlikowski D, Pellegrini N, Prigent H, Laforêt P, Carlier R, Carlier P, Eymard B, Lofaso F, Annane D: Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul Disord 2011, 21:477-482.
• [26]Regnery C, Kornblum C, Hanisch F, Vielhaber S, Strigl-Pill N, Grunert B, Müller-Felber W, Glocker FX, Spranger M, Deschauer M, Mengel E, Schoser B: 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 2012, 35:837-845. 31
• [27]Strothotte S, Strigl-Pill N, Grunert B, Kornblum C, Eger K, Wessig C, Deschauer M, Breunig F, Glocker FX, Vielhaber S, Brejova A, Hilz M, Reiners K, Müller-Felber W, Mengel E, Spranger M, Schoser B: Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 2010, 257:91-97.
• [28]van Capelle CI, Winkel LP, Hagemans ML, Shapira SK, Arts WF, van Doorn PA, Hop WC, Reuser AJ, van der Ploeg AT: Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 2008, 18:447-452.
• [29]van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA: A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med 2010, 362:1396-1406.
• [30]Kroos MA, Pomponio RJ, Hagemans ML, Keulemans JL, Phipps M, DeRiso M, Palmer RE, Ausems MG, Van der Beek NA, Van Diggelen OP, Halley DJ, Van der Ploeg AT, Reuser AJ: Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype. Neurology 2007, 68:110-111.
• [31]Okumiya T, Keulemans JL, Kroos MA, Van der Beek NM, Boer MA, Takeuchi H, Van Diggelen OP, Reuser AJ: A new diagnostic assay for glycogen storage disease type II in mixed leukocytes. Mol Genet Metab 2006, 88:22-28.
• [32]van Diggelen OP, Oemardien LF, van der Beek NA, Kroos MA, Wind HK, Voznyi YV, Burke D, Jackson M, Winchester BG, Reuser AJ: Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates. J Inherit Metab Dis 2009, 32:416-423.
• [33]Kroos M, Pomponio RJ, van Vliet L, Palmer RE, Phipps M, Van der Helm R, Halley D, Reuser A, GAA Database Consortium: Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating. Hum Mutat 2008, 29:E13-E26.
• [34]van der Ploeg RJ, Fidler V, Oosterhuis HJ: Hand-held myometry: reference values. J Neurol Neurosurg Psychiatry 1991, 54:244-247.
• [35]Medical Research Council: Aids to examination of the peripheral nervous system. Memorandum no. 45. Her Majesty's Stationary Office, London; 1976.
• [36]van Capelle CI, van der Beek NA, de Vries JM, van Doorn PA, Duivenvoorden HJ, Leshner RT, Hagemans ML, van der Ploeg AT: The quick motor function test: a new tool to rate clinical severity and motor function in Pompe patients. J Inherit Metab Dis 2012, 35:317-323.
• [37]American Thoracic Society/European Respiratory Society: ATS/ERS Statement on respiratory muscle testing. Am J Respir Crit Care Med 2002, 166:518-624.
• [38]Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC: Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European respiratory society. Eur Respir J 1993, 16(S):5.
• [39]Wilson SH, Cooke NT, Edwards RH, Spiro SG: Predicted normal values for maximal respiratory pressures in caucasian adults and children. Thorax 1984, 39:535-538.
• [40]de Vries JM, Van der Beek NA, Kroos MA, Ozcan L, van Doorn PA, Richards SM, Sung CC, Brugma JD, Zandbergen AA, van der Ploeg AT, Reuser AJ: High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab 2010, 101:338-345.
• [41]Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, Van Doorn PA, De Jong G, Hop W, Smit GP, Shapira SK, Boer MA, van Diggelen OP, Reuser AJ, Van der Ploeg AT: Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol 2004, 55:495-502.
• [42]Miller AE, MacDougall JD, Tarnopolsky MA, Sale DG: Gender differences in strength and muscle fiber characteristics. Eur J Appl Physiol Occup Physiol 1993, 66:254-262.
• [43]Sale DG, MacDougall JD, Alway SE, Sutton JR: Voluntary strength and muscle characteristics in untrained men and women and male bodybuilders. J Appl Physiol 1987, 62:1786-1793.